Nonprofit drugmaker Civica Rx unveils plans for insulin biosimilars, $30 per vial
Civica Rx plans to make lower cost versions of three branded insulin products, biosimilars that are expected to reach the market in 2024. In addition to $30 vials, Civica plans to sell pen cartridges at $55 for a box of five.
